Welcome to LookChem.com Sign In|Join Free

CAS

  • or

230617-66-0

Post Buying Request

230617-66-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

230617-66-0 Usage

General Description

2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine is a chemical compound with the molecular formula C11H14ClN2. It is a chlorinated pyridine derivative that contains a pyrrolidine group attached to the fifth position of the pyridine ring. This chemical has been studied for its potential use in pharmaceutical applications, particularly in the development of new drugs. Its unique structure and properties make it a target for medicinal chemistry research, as it may have potential therapeutic uses. The compound's synthesis and characterization are important for understanding its properties and potential applications in the field of medicinal chemistry.

Check Digit Verification of cas no

The CAS Registry Mumber 230617-66-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,3,0,6,1 and 7 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 230617-66:
(8*2)+(7*3)+(6*0)+(5*6)+(4*1)+(3*7)+(2*6)+(1*6)=110
110 % 10 = 0
So 230617-66-0 is a valid CAS Registry Number.

230617-66-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-chloro-5-(pyrrolidin-1-ylmethyl)pyridine

1.2 Other means of identification

Product number -
Other names 1-(6-chloro-pyridin-3-ylmethyl)-pyrrolidine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:230617-66-0 SDS

230617-66-0Downstream Products

230617-66-0Relevant articles and documents

HETEROAROMATIC ELECTROPHILES AND METHODS OF USING THEREOF

-

Page/Page column 50, (2018/09/18)

Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.

INDOLIZINE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS

-

Paragraph 0314; 0315; 0316; 0323; 0324; 0325, (2015/12/31)

Compounds of formula (I), defined herein, inhibit phosphoinositide 3-kinases (PI3K) and are useful for the treatment of disorders associated with PI3K enzymes.

Substituted pyridines as modulators of the mammalian neuronal nicotinic acetylcholine receptor

-

, (2008/06/13)

Novel compounds are provided that modulate the neuronal nicotinic acetylcholine receptor (nAChR), particularly the mammalian nAChR (m-nAChR). The compounds are substituted pyridine derivatives such as analogs of 1-[(6-chloro-3-pyridinyl)methyl]-2-imidazolidine and 1-[(6-chloro-3-pyridinyl)methyl]-2-iminothiazole. Methods of using the novel m-nAChR modulators are also provided, including methods of using the compounds as m-nAChR probes and as therapeutic agents to treat mammalian individuals suffering from conditions, disorders or diseases that are responsive to administration of an m-nAChR modulator. The compounds are useful in treating (1) CNS disorders such as Alzheimer's disease, AIDS-associated dementia, Tourette's Syndrome, attention deficit disorder, and attention deficit disorder, (2) inflammation and inflammatory diseases, (3) conditions caused by or associated with smooth muscle contractions, and (4) withdrawal symptoms associated with cessation of chemical substance abuse. The compounds are also useful as non-opiate analgesics, to treat mild, moderate or severe pain. Pharmaceutical formulations containing an m-nAChR modulator of the invention are provided as well.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 230617-66-0